Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt

Neoplasms Clinical Trial

Official title:

Ewing Sarcoma Family of Tumors (ESFT): A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04300179
• Other study ID #: ESFT_Upp_Egypt
• Status: Completed
• Start date: July 7, 2020
• Est. completion date: December 16, 2020

Study information

• Verified date: December 2020
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study is to identify demographic & disease characteristics in pediatric oncology patients diagnosed with Ewing Sarcoma Family of Tumors (ESFT) & treatment outcomes in these patients.

Description:

Ewing sarcoma (ES) and peripheral primitive neuroectodermal tumor (PNET), Both entities that currently comprise the same spectrum of neoplastic diseases known as the Ewing sarcoma family of tumors (EFT), were originally described as distinct clinicopathologic entities. Primitive neuroectodermal tumors (PNETs) first described in 1918 by Stout as a malignant tumor arising from major nerve. Later, in 1921, ES was described as an undifferentiated tumor involving the diaphysis of long bones. It was also reported to arise in soft tissue (extraosseous ES). EFT is aggressive malignant small round cell tumors of bone and soft-tissue that predominantly affecting children and young adults.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 59
• Est. completion date: December 16, 2020
• Est. primary completion date: December 16, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 19 Years

Eligibility

Inclusion Criteria:

• Patients whose age less than 19 years. Patients diagnosed with Ewing Sarcoma Family of Tumors (ESFT).

Exclusion Criteria:

• Patients whose age more than 19 years. Patients diagnosed with other bone & soft tissue neoplasms.

Related Conditions & MeSH terms

• Bone Neoplasms
• Neoplasms
• Sarcoma
• Sarcoma, Ewing
• Soft Tissue Neoplasms

Locations

Country	Name	City	State
Egypt	South Egypt Cancer Institute	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival (OS)	Participants will be retrospectively followed forward in time from the date of initiation of treatment till death from any cause, an expected average of 5 years	From date of treatment initiation until the date of death from any cause or patients censored at last follow up, whichever came first, assessed up to 60 months
Primary	Event Free Survival (EFS)	Participants will be retrospectively followed forward in time from the date of initiation of treatment till occurrence of an event from any cause (tumor progression, relapse) or death, an expected average of 5 years	From date of treatment initiation until the date of event from any cause or patients censored at last follow up, whichever came first, assessed up to 60 months